Send to a Friend Font Size: Increase Decrease

Viking Global Investors

Viking Global Investors 's Portfolio

Last Updated on 5/16/11 @ 05:55pm

Ticker	# of Shares	Price	Value
	143,085,126	$195.32	$27,947,386,811
	120,000,000	$195.32	$23,438,400,000
	75,238,700	$195.32	$14,695,622,884
MU	4,424,339	$1,074.89	$4,755,677,748
STX	3,186,400	$848.99	$2,705,221,736
V	7,140,286	$360.66	$2,575,215,549
GE	7,138,176	$309.56	$2,209,693,763
	9,798,229	$195.32	$1,913,790,089
PM	9,055,492	$187.46	$1,697,542,531
FTNT	7,689,287	$180.95	$1,391,376,483
View Additional Portfolio Information »

Viking Global Investors is a long/short equity hedge fund. The fund employs a bottom-up fundamental stock-picking strategy for its investments in equities in the U.S. and Europe. It focuses on the financial, telecommunication, media, technology, and consumer sectors. Viking Global Investors is based in New York and was founded in October, 1999 by Andreas Halvorsen, David Ott, and Brian Olson.

Messers. Halvorsen, Ott, and Olson worked together at Tiger Management Corp. All three left Tiger in early 1999.

Login to help us fill in information about this entity.

Form 8-K Viking Global Technologi For: Sep 30 Oct 2, 2026 05:01PM

Form D/A Viking Global Opportunit Oct 2, 2026 05:00PM

Form D/A Viking Global Equities Oct 2, 2026 04:56PM

Form D/A Viking Global Equities Oct 2, 2026 04:55PM

Form D/A Viking Global Opportunit Oct 2, 2026 04:53PM

View Older Stories

Oct 2, 2026 09:17AM Form D/A Viking Global Equities
Sep 16, 2026 04:34PM Form SCHEDULE 13G REGAL REXNORD CORP Filed by: VIKING GLOBAL INVESTORS LP
Sep 14, 2026 05:00PM Form 8-K Viking Global Technologi For: Sep 08
Aug 31, 2026 12:13PM Form N-PX VIKING GLOBAL INVESTORS For: Jun 30
Aug 14, 2026 04:17PM Form SCHEDULE 13G/A Inhibrx Biosciences, Filed by: VIKING GLOBAL INVESTORS LP
Aug 14, 2026 04:17PM Form SCHEDULE 13G/A Oruka Therapeutics, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Aug 14, 2026 04:05PM Form 13F-HR VIKING GLOBAL INVESTORS For: Jun 30
Jul 10, 2026 07:03PM Form SCHEDULE 13D/A BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Jun 12, 2026 05:35PM Form SCHEDULE 13D STANDARD BIOTOOLS INC. Filed by: VIKING GLOBAL INVESTORS LP
May 18, 2026 07:32PM Form SCHEDULE 13G Artiva Biotherapeutics, Filed by: VIKING GLOBAL INVESTORS LP
May 18, 2026 08:01AM TRIANA Biomedicines appoints Mohan Bala as chief operating officer
May 15, 2026 05:52PM Form SCHEDULE 13G/A Fortive Corp Filed by: VIKING GLOBAL INVESTORS LP
May 15, 2026 05:52PM Form SCHEDULE 13G/A Veradermics, Inc Filed by: VIKING GLOBAL INVESTORS LP
May 15, 2026 05:52PM Form SCHEDULE 13G/A TIC Solutions, Inc. Filed by: VIKING GLOBAL INVESTORS LP
May 15, 2026 05:52PM Form SCHEDULE 13G/A Sionna Therapeutics, Filed by: VIKING GLOBAL INVESTORS LP
May 15, 2026 05:52PM Form SCHEDULE 13G/A Rallybio Corp Filed by: VIKING GLOBAL INVESTORS LP
May 15, 2026 05:52PM Form SCHEDULE 13G/A Ginkgo Bioworks Holdings Filed by: VIKING GLOBAL INVESTORS LP
May 15, 2026 05:52PM Form SCHEDULE 13G/A Oruka Therapeutics, Inc. Filed by: VIKING GLOBAL INVESTORS LP
May 15, 2026 05:52PM Form SCHEDULE 13G/A Inhibrx Biosciences, Filed by: VIKING GLOBAL INVESTORS LP
May 15, 2026 05:52PM Form SCHEDULE 13G/A Chewy, Inc. Filed by: VIKING GLOBAL INVESTORS LP
May 15, 2026 05:51PM Form SCHEDULE 13G/A PepGen Inc. Filed by: VIKING GLOBAL INVESTORS LP
May 15, 2026 05:51PM Form SCHEDULE 13G/A Pharvaris N.V. Filed by: VIKING GLOBAL INVESTORS LP
May 15, 2026 05:51PM Form SCHEDULE 13G/A STANDARD BIOTOOLS INC. Filed by: VIKING GLOBAL INVESTORS LP
May 15, 2026 05:51PM Form SCHEDULE 13G/A Adaptive Biotechnologies Filed by: VIKING GLOBAL INVESTORS LP
May 15, 2026 05:51PM Form SCHEDULE 13G/A Oric Pharmaceuticals, Filed by: VIKING GLOBAL INVESTORS LP
May 15, 2026 04:28PM Form 13F-HR VIKING GLOBAL INVESTORS For: Mar 31
May 8, 2026 06:52AM Artiva Biotherapeutics prices $300 million stock and warrant offering
May 1, 2026 05:39PM Form SCHEDULE 13G Altimmune, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Apr 22, 2026 07:14PM Form SCHEDULE 13G LENNOX INTERNATIONAL Filed by: VIKING GLOBAL INVESTORS LP
Apr 13, 2026 09:00AM Orum Therapeutics adds two directors to board
Apr 2, 2026 06:40PM Form SCHEDULE 13D/A BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Mar 2, 2026 08:01AM Rallybio and Candid Therapeutics announce merger agreement
Feb 17, 2026 08:47PM Form SCHEDULE 13D/A BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Feb 17, 2026 05:00PM Form 13F-HR VIKING GLOBAL INVESTORS For: Dec 31
Feb 17, 2026 04:28PM Form SCHEDULE 13G/A SAIA INC Filed by: VIKING GLOBAL INVESTORS LP
Feb 17, 2026 04:28PM Form SCHEDULE 13G/A Primo Brands Corp Filed by: VIKING GLOBAL INVESTORS LP
Feb 17, 2026 04:28PM Form SCHEDULE 13G/A Inhibrx Biosciences, Filed by: VIKING GLOBAL INVESTORS LP
Feb 17, 2026 04:28PM Form SCHEDULE 13G/A NewAmsterdam Pharma Co Filed by: VIKING GLOBAL INVESTORS LP
Feb 17, 2026 04:28PM Form SCHEDULE 13G/A Rallybio Corp Filed by: VIKING GLOBAL INVESTORS LP
Feb 12, 2026 04:55PM Form SCHEDULE 13G Veradermics, Inc Filed by: VIKING GLOBAL INVESTORS LP
Jan 13, 2026 07:09PM Form SCHEDULE 13G REGAL REXNORD CORP Filed by: VIKING GLOBAL INVESTORS LP
Dec 30, 2025 06:31PM Form SCHEDULE 13G Chewy, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Nov 14, 2025 04:58PM Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Nov 14, 2025 04:57PM Form SCHEDULE 13D/A BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Nov 14, 2025 04:57PM Form SCHEDULE 13G/A BIOMARIN PHARMACEUTICAL Filed by: VIKING GLOBAL INVESTORS LP
Nov 14, 2025 04:57PM Form SCHEDULE 13G/A REGAL REXNORD CORP Filed by: VIKING GLOBAL INVESTORS LP
Nov 14, 2025 04:57PM Form SCHEDULE 13G/A Roivant Sciences Ltd. Filed by: VIKING GLOBAL INVESTORS LP
Nov 14, 2025 04:57PM Form SCHEDULE 13G/A Fortive Corp Filed by: VIKING GLOBAL INVESTORS LP
Nov 14, 2025 04:44PM Form 13F-HR VIKING GLOBAL INVESTORS For: Sep 30
Nov 10, 2025 07:19AM Galecto completes Damora acquisition with $285 million funding round

View Older Stories

Nasdaq		15000.33
	+57.68	(+0.39%)

S&P 500		4486.55
	+7.02	(+0.16%)

Market Snapshot

Free News Feed